Single-Payer System Solutions
In addition to conducting clinical research, Inmedix UK seeks to consider the health economic impact of our approach in a single-payer system.
Within an economy one sixth the size of the Unites States, the cost of autoimmune disease treatment is an exceptional challenge in the UK. Inmedix looks forward to working with our UK colleagues and Inmedix Scientific Advisory Board members, Professors Peter Taylor (Oxford) and Ernest Choy (Cardiff), the National Rheumatoid